Progyny expects Q4 2024 revenue, net income, Adjusted EBITDA slightly above prior guidance

Progyny, Inc.

Company updates guidance at JPM Healthcare Conference; Q4 results expected slightly above November ranges.
Previous guidance assumed member activity flat to down vs Q3 2024; improved pacing drove the beat.
CEO Pete Anevski to present on Jan 14, 2025 at 7:30 a.m. PT; audiocast available on investor site.
No specific dollar amounts or revised ranges provided in the press release.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.